Dr. Tsukamoto has been a groundbreaking researcher in the field of stem cell biology for more than twenty years. She joined the Company in February 1998 as Senior Director, Scientific Operations, and has held several leadership roles at the Company, most recently as Executive Vice President of Research and Development since September 2008. Dr. Tsukamoto was a co-discoverer of the human hematopoietic stem cell while at SyStemix, Inc., and played a leading role at StemCells in the isolation of the human neural stem cell as well as populations of human liver and pancreatic cells with stem cell-like properties. Dr. Tsukamoto received her doctorate from the University of California, Los Angeles, and did postdoctoral research at the University of California, San Francisco.
In his new role, Dr. Salinas will focus on accelerating completion of the Company's ongoing trials in spinal cord injury and age-related macular degeneration, as well as advancing the Company's plans for a Phase II study in Pelizaeus-Merzbacher disease. Dr. Salinas has more than 20 years of experience and expertise developing therapeutic products for central nervous system (CNS) disorders in many key jurisdictions worldwide, including the United States, Canada, the European Union, and Japan. Under his leadership, 15 programs obtained regulatory approval in the United States and other major international markets. Prior to joining StemCells, Dr. Salinas was Executive Vice President, Head of Development, and Chief Medical Officer of Elan Pharmaceuticals. Before joining Elan, Dr. Salinas was Senior Vice President, Research and Development and Chief Medical Officer of Adolor Coproration; Executive Vice President, Speciality Pharma, Research and Development and Chief Scientific Officer of Shire plc; and held roles of increasing responsibility in research and development at Wyeth-Ayerst Research, including head of worldwide CNS product development. Dr. Salinas earned his medical degree from the University of Buenos Aires, Argentina, performed a residency in psychiatry in Paris at the Clinique des Maladies Mentales et de l'Encéphale, and obtained a master's degree in pharmacology from the Université Pierre et Marie Curie, Académie de Paris, France.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts